BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32200037)

  • 1. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
    Xi Y; Yuan P; Li T; Zhang M; Liu MF; Li B
    Cancer Lett; 2020 Jun; 479():112-122. PubMed ID: 32200037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
    Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
    Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
    Pérez-Torras S; García-Manteiga J; Mercadé E; Casado FJ; Carbó N; Pastor-Anglada M; Mazo A
    Biochem Pharmacol; 2008 Aug; 76(3):322-9. PubMed ID: 18589402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
    Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA
    Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
    Tsujie M; Nakamori S; Nakahira S; Takeda S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Pancreas; 2006 Aug; 33(2):142-7. PubMed ID: 16868479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
    Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
    Xiao JC; Zhang TP; Zhao YP
    Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
    D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
    Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
    Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
    Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
    Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
    J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
    Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
    Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
    Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.